ReviewCancer medicine2023
Anti-tumor effects of miR-34a by regulating immune cells in the tumor microenvironment.
Review in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 16 citations in OpenAlex.
- Targeting lncRNAs to Overcome Cancer Therapy Resistance: Advances in RNA Therapeutics and Delivery Strategies.Cancers · 2026Review
- Advances in the study of the breast carcinoma exosomal microRNAs: From basic mechanisms to clinical applications (Review).International journal of oncology · 2026Review
- Advances and challenges in biomarker guided management of triple-negative breast cancer in the era of neoadjuvant chemo-immunotherapy.Frontiers in oncology · 2026Review
- Effects of sesamin on the chemosensitivity, invasiveness and immune evasion mechanism of human lung adenocarcinoma.International journal of molecular medicine · 2025Article
- Immune checkpoint inhibitors in cancer therapy: what lies beyond monoclonal antibodies?Medical oncology (Northwood, London, England) · 2025Review
- Emerging Tumor Biomarkers in Pancreatic Cancer and Their Clinical Implications.Current issues in molecular biology · 2025Review
- Regulation of Different Types of Cell Death by Noncoding RNAs: Molecular Insights and Therapeutic Implications.ACS pharmacology & translational science · 2025Review
- Non-coding RNAs, a double-edged sword in breast cancer prognosis.Cancer cell international · 2025Review
- A comparison of the expression patterns and diagnostic capability of the ncRNAs NEAT1 and miR-34a in non-obstructive azoospermia and severe oligospermia.Human genomics · 2025Article
- Diagnostic value of miR-34a in Mycoplasma pneumoniae pneumonia in children and its correlation with rehabilitation effect.Journal of cardiothoracic surgery · 2024Article
- Understanding the role of miRNAs in cervical cancer pathogenesis and therapeutic responses.Frontiers in cell and developmental biology · 2024Review
- Mechanisms and technologies in cancer epigenetics.Frontiers in oncology · 2024Review
- Anti-tumor effects of miR-34a by regulating immune cells in the tumor microenvironment.Cancer medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant tumors pose a serious threat to human health. The development of malignant tumors is characterized by uncontrolled cell division and immune evasion. The micro-ribonucleic acid-34a (miR-34a) is a small noncoding single-stranded ribonucleic acid that is ubiquitously present in normal human tissues. However, it has been confirmed to be dysregulated in a variety of tumor cells. Numerous research have revealed the importance of miR-34a in the treatment of various malignancies. MiR-34a deletion can hasten the growth of tumors whereas miR-34a overexpression suppresses the proliferation, invasion, and migration of cancer cells. Moreover, more recent studies have highlighted its role in immunity and investigated its applicability to particular tumors. Through various immune cells, factors, and other mechanisms, miR-34a can inhibit tumor carcinogenesis. In view of the important role of miR-34a in tumors, this research reviewed the aspects of miR-34a regulation of tumor immune microenvironment to exert anti-tumor effects in order to clarify the potential immunotherapy value of miR-34a in tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.